BALTIMORE Following an investigation conducted by U.S. Immigration and Customs Enforcement (ICE) Homeland Security Investigations (HSI), the U.S. Attorneys Office for the District of Maryland announced today the seizure of two domain names, mordernatx.com and regeneronmedicals.com, which purported to be the websites of actual biotechnology companies developing treatments for the COVID-19 virus. These spoofed websites were used to collect the personal information of individuals visiting the sites, in order to use the information for nefarious purposes, including fraud, phishing attacks, and/or deployment of malware. Individuals visiting those sites now will receive a message that the site has been seized by the federal government and be redirected to another site for additional information.
Our cadre of highly skilled special agents, paired with invaluable private sector partnerships garnered through the National Intellectual Property Rights Coordination Center provide an effective strategy to help identify, disrupt and dismantle illegitimate domains used to defraud potential consumers. said ICEs Homeland Security Investigations Executive Associate Director Derek N. Benner. Under Operation Stolen Promise, ICE HSI utilized its broad investigative authority to protect consumers from the increasing and evolving threat posed by COVID-19-related fraud and criminal activity. Now, under Operation Stolen Promise 2.0, HSIs focus has expanded to combat the next wave of anticipated fraud related to the COVID-19 vaccine and other treatments. This operation illustrates the ongoing efforts of the National Intellectual Property Rights Coordination Center, private industry and international law enforcement agencies in keeping our communities safe and free from corruption. Often, this battle is fought behind the scenes and unknown to the general public. Though, the global population can be assured that our mission remains firmly committed to protecting their health and safety, no matter what.
The U.S. Attorneys Office and our law enforcement partners are committed to bringing to justice the criminals that try to take advantage of this global pandemic to line their pockets at the expense of the most vulnerable, said U.S. Attorney Robert K. Hur. I urge citizens to remain vigilant. Dont provide personal information or click on websites or links contained in unsolicited e-mails. Dont become a victim.
These individuals took advantage of fear during the global pandemic and attempted to steal personal information for nefarious purposes, said HSI Baltimore Special Agent in Charge John Eisert. From the cyber realm to counterfeit medication to financial crime, we are committed to detecting, investigating, and disrupting all types of fraud related to the COVID-19 pandemic.
According to the affidavits filed in support of these seizures, these investigations began in early December 2020, after corporate security for one of the companies located the spoof website and contacted ICE HSIs Intellectual Property Rights Center (IPRC) and the HSI Cyber Crimes Center (C3), and the other website was located during an ongoing operation targeting suspicious publicly reachable websites by ICE HSI C3. The cases were referred to HSI Baltimore for investigation.
Specifically, on December 10, 2020, the Global Head of Corporate Security for a biotechnology company headquartered in Cambridge, Massachusetts, which has developed a COVID-19 vaccine that is awaiting approval by the U.S. Food and Drug Administration (FDA), contacted HSI IPRC and C3 by e-mail to report that the companys Cybersecurity Team had detected the domain name mordernatx.com, a fraudulent replication of the companys website. A review of that websites online content displayed the name and trademarked logos for the biotechnology company. As detailed in the affidavit, the logos, markings, colors, and text of the mordernatx.com webpage show no substantive differences from the genuine company websites landing page, other than the fraudulent website has a slight misspelling of the companys name. However, individuals who click on the Contact Us tab, are redirected to an entry form requesting information such as name, company/institution, title, phone, e-mail, and comments/questions. Additional investigation revealed that the mordernatx.com domain name was registered on about December 8, 2020, through a company headquartered in Kuala Lumpur, Malaysia, with no personal information for the registrar listed.
The second domain name seized, regeneronmedicals.com, was located on December 9, 2020, during an ongoing investigation targeting suspicious publicly reachable websites. Investigators found that the subject domain name contained the name and trademarked logos, and was visually similar to, the webpage of a biotechnology company headquartered in Westchester County, New York, which was granted an emergency use authorization by the FDA for an antibody cocktail used to treat COVID-19 in high-risk patients with mild to moderate COVID-19. Further investigation revealed that the subject domain name contained two e-mail addresses and a telephone number not found on the official company website. The phone number appears to be a Voice over IP (VOIP) number. In addition, the Contact Us page on the regeneraonmedicals.com site directs Healthcare professionals, patients or caregivers requesting specific product information, reporting an adverse event or reporting a product complaint to contact the Medical Department at the VOIP number. The same Contact Us tab also provides a link to submit medical inquiries which directs users to a page that is different from the same page on the official website. Investigators also found that the subject domain name was registered on December 6, 2020, and lists the registrant as an individual residing in Onitsha Anambra, Nigeria.
By seizing these sites, the government has prevented third parties from acquiring the names and using them to commit additional crimes, as well as prevented third parties from continuing to access the sites in their present form.
ICE HSI launched Operation Stolen Promise in April 2020 to protect the Homeland from the increasing and evolving threat posed by COVID-19-related fraud and criminal activity. As of November 25, 2020, the agency has seized more than $26 million in illicit proceeds; made 170 arrests; executed 148 search warrants and analyzed more than 69,000 COVID-19 domain names. Working with U.S. Customs and Border Protection, more than 1,600 shipments of mislabeled, fraudulent, unauthorized or prohibited COVID-19 test kits and other related items have been seized. For its role in the operation, C3 applies technological, operational, and criminal investigative expertise, products, and services to target the criminals and organizations attempting to commit cybercrimes and exploitation related to COVID-19.
Federal law enforcement is united in its efforts to fight against COVID-19 fraud. ICE HSI has identified tips to recognize and report COVID-19 fraud. If you think you are a victim of a fraud or attempted fraud involving COVID-19, you may also call the National Center for Disaster Fraud Hotline at 1-866-720-5721 or for more information e-mail justice.gov/coronavirus.
See the rest here:
ICE investigation led to seizure of two websites of biotechnology companies developing treatments for COVID-19 vaccine - The Newport Daily Express
- Research shows need for better mpox protection in HIV-positive patients - The Pharma Letter - April 5th, 2025
- Marine Biotechnology Market to Reach $10.37 Bn by 2032 with 6.2% CAGR - openPR.com - April 5th, 2025
- Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana... - April 5th, 2025
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class... - April 5th, 2025
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024